ARCH's latest biotech, targeting cancer recurrence, emerges from Columbia professor who worked on Biden's moonshot

TFC Therapeutics, a new ARCH Venture Partners biotech, on Thursday unveiled a mission to thwart the return of cancer and its …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ARCH's lat­est biotech, tar­get­ing can­cer re­cur­rence, emerges from Co­lum­bia pro­fes­sor who worked on Biden's moon­shot